Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

AVDL vs ACRS: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

AVDL Wins Head-to-Head Institutional Verdict (5–0 across 6 Pillars · 9–0 Matrix Metrics)

AVDL Overall Winner 6-Pillar Tally: AVDL 5 – 0 ACRS (1 Tie) Matrix Metrics: AVDL 9 – 0 ACRS

As of Nov 20, 2026, Avadel Pharmaceuticals plc Ordinary Share (AVDL) is the stronger overall head-to-head candidate over Aclaris Therapeutics, Inc. (ACRS) in the Tradestie Institutional Equity Comparison Engine, winning 9–0 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). AVDL carries a Unified Composite Score of 62.9/100 (BUY) at $21.64 (28.8x Forward P/E, 2.5% operating margin), whereas ACRS carries 45.2/100 (HOLD) at $3.44 (N/M Forward P/E, -1412.4% operating margin).

  • Technical & Structure Timing Caution: AVDL trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 62.3); meanwhile ACRS is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 39.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About AVDL vs ACRS
AVDL NASDAQ Head-to-Head Winner
Avadel Pharmaceuticals plc Ordinary Share
Pharmaceutical Preparations
$21.64
+0.05% 1D
Market Cap $2.1B
TTM Revenue $249M
Forward P/E 28.8x
Beta / 30D Vol 0.14β · 2% Vol
Unified Composite Score
62.9 / 100 BUY
Tech 75.0 Fund 60.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (1.4% over 20 days), RSI 62
RSI-14: 62.3 · SMA20: $21.56 · SMA50: $21.50
ACRS NASDAQ
Aclaris Therapeutics, Inc.
Pharmaceutical Preparations
$3.44
-1.71% 1D
Market Cap $555.1M
TTM Revenue $6.4M
Forward P/E N/M
Beta / 30D Vol 1.42β · 69% Vol
Unified Composite Score
45.2 / 100 HOLD
Tech 42.0 Fund 57.0 Flow 64.0 Mom 70.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -17.6%), weak momentum, RSI 39
RSI-14: 39.0 · SMA20: $3.82 · SMA50: $4.21

6-Pillar Scorecard Institutional Category Breakdown (AVDL 5 – 0 ACRS)

Columns: Metric · AVDL · ACRS
1. Valuation Multiples AVDL
Forward P/E 28.8x N/M
Trailing P/E 16.8x N/M
PEG Ratio 0.07x N/M
EV / Revenue 8.5x 86.7x
2. Growth & Scale AVDL
Revenue Growth (YoY) +54.9% -55.1%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $249M $6.4M
Market Cap $2.1B $555.1M
3. Profitability & Quality AVDL
Gross Margin 94.9% N/A
Operating Margin 2.5% -1412.4%
Net Profit Margin -0.1% 0.0%
Return on Equity (ROE) -0.3% -55.5%
4. Balance Sheet & Cash Flow AVDL
Cash Generation (TTM) $2.7M EBITDA -$75M
Cash Flow Margin 1.1% EBITDA Mgn N/A
Net Cash / Leverage $1.01 Book/Sh · -0.3% ROE $1.11 Book/Sh · -55.5% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning AVDL
Options Structure Phase UNCLASSIFIED BREAKDOWN
Current IV / %ile 2.4% (<1st %ile) 60.7% (<1st %ile)
Put/Call OI Skew N/A 40.79x (Put-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markup DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Drug Manufacturers - Specialty & Generic Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: AVDL (9) vs ACRS (0)
Institutional Metric AVDL ACRS Criterion Row Edge
Market Capitalization
Scale
$2.1B $555.1M Larger Scale AVDL
Trailing P/E Ratio
Valuation
16.8x N/M Lower Multiple AVDL
Forward P/E Ratio
Valuation
28.8x N/M Lower Multiple AVDL
Revenue Growth (YoY)
Growth
+54.9% -55.1% Higher Growth AVDL
Operating Margin (TTM)
Profitability
2.5% -1412.4% Higher Margin AVDL
Net Profit Margin
Profitability
-0.1% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-0.3% -55.5% Higher ROE AVDL
52-Week Range Position
Momentum
89% ($6–$24) 26% ($2–$7) Stronger Trend AVDL
Beta / 30D Volatility
Risk Regime
0.14β · 2% Vol 1.42β · 69% Vol Lower Realized Risk AVDL
Unified Institutional Score
Composite Signal
62.9 / 100 (BUY) 45.2 / 100 (HOLD) Higher Composite AVDL
Trailing 12M Revenue (USD)
Operating Scale
$249M $6.4M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
94.9% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
0.07x PEG · 8.5x EV/Rev N/M PEG · 86.7x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$2.7M EBITDA ($1.01 Book/Sh · -0.3% ROE) -$75M ($1.11 Book/Sh · -55.5% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ACRS +26.79 pp
AVDL: +0.65% · ACRS: +27.44%
3M Horizon ACRS +44.12 pp
AVDL: -6.32% · ACRS: +37.8%
6M Horizon ACRS +44.12 pp
AVDL: -6.32% · ACRS: +37.8%
1Y Horizon ACRS +44.12 pp
AVDL: -6.32% · ACRS: +37.8%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on AVDL vs ACRS. Trailing 12-month operating profitability (AVDL 2.5% vs ACRS -1412.4%) and valuation multiples (AVDL 28.8x vs ACRS N/M Forward P/E) are benchmarked directly in Pillar 4 below.

AVDL ADR TTM Benchmark FX-Normalized USD
TTM Revenue$249M
Gross Margin94.9%
Op. Margin2.5%
ROE / Fwd P/E-0.3% · 28.8x
ACRS ADR TTM Benchmark FX-Normalized USD
TTM Revenue$6.4M
Gross MarginN/A
Op. Margin-1412.4%
ROE / Fwd P/E-55.5% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
AVDL UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 2.4%
IV Percentile <1st %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact AVDL Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ACRS BREAKDOWN
62d in phase · OBV DISTRIBUTION
Current IV 60.7%
IV Percentile <1st %ile
Put/Call OI Skew 40.79x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact ACRS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
AVDL Moat Profile Cyclical / Execution-Driven Positioning
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $2.1B market capitalization and 2.5% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
ACRS Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $555.1M market capitalization and -1412.4% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ AVDL vs ACRS Key Questions & Quantitative Answers

As of Nov 20, 2026, Avadel Pharmaceuticals plc Ordinary Share (AVDL) is the stronger overall head-to-head candidate over Aclaris Therapeutics, Inc. (ACRS) in the Tradestie Institutional Equity Comparison Engine, winning 9–0 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). AVDL carries a Unified Composite Score of 62.9/100 (BUY) at $21.64 (28.8x Forward P/E, 2.5% operating margin), whereas ACRS carries 45.2/100 (HOLD) at $3.44 (N/M Forward P/E, -1412.4% operating margin). Technical & Structure Timing Caution: AVDL trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 62.3); meanwhile ACRS is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 39.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

AVDL leads the Growth & Scale pillar: AVDL posts +54.9% YoY revenue growth and +0.0% YoY earnings growth on $249M TTM revenue (94.9% gross margin, 2.5% operating margin), compared with ACRS at -55.1% YoY revenue growth and +0.0% YoY earnings growth on $6.4M TTM revenue (N/A gross margin, -1412.4% operating margin). On trailing 12-month operating scale, AVDL generates $249M in USD-normalized revenue versus $6.4M for ACRS. In operating R&D and SG&A reinvestment, AVDL deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ACRS.

AVDL screens cheaper on headline valuation multiples. AVDL trades at 28.8x Forward P/E, 16.8x Trailing P/E, 0.07x PEG, and 8.5x EV/Revenue (1.1% EBITDA margin), whereas ACRS trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 86.7x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against AVDL (-0.3% ROE) versus ACRS (-55.5% ROE) capital efficiency.

In options market volatility and institutional positioning, AVDL carries 2.4% implied volatility (<1st %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.14β · 2% Vol realized risk). By comparison, ACRS carries 60.7% implied volatility (<1st %ile, Compressed (<25th %ile)), a 40.79x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.42β · 69% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.